COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01084824
Recruitment Status : Completed
First Posted : March 11, 2010
Last Update Posted : March 11, 2010
Information provided by:
North Idaho Dermatology

Brief Summary:
The purpose of the study was to see if liquid nitrogen, a commonly used treatment for warts, is more effective if it is used alone, or if it is more effective if combined with cantharidin, a topical treatment also commonly used for warts (verruca vulgaris).

Condition or disease Intervention/treatment Phase
Verruca Vulgaris Drug: Liquid nitrogen and cantharidin Drug: Liquid nitrogen and topical placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Clinical Trial Examining the Efficacy of Treatment of Cutaneous Verruca Vulgaris in Adult Patients With Combined Liquid Nitrogen Cryotherapy and Topically Applied Cantharidin
Study Start Date : June 2007
Actual Primary Completion Date : June 2008
Actual Study Completion Date : September 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Warts

Arm Intervention/treatment
Active Comparator: Liquid nitrogen and canthardin
Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterwards.
Drug: Liquid nitrogen and cantharidin
Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterward.

Placebo Comparator: Liquid nitrogen and placebo
Liquid nitrogen applied to wart(s) then placebo vehicle afterwards.
Drug: Liquid nitrogen and topical placebo
Liquid nitrogen applied to wart(s), then placebo vehicle applied thereafter.

Primary Outcome Measures :
  1. Percentage of common warts cleared [ Time Frame: 12 weeks ]
    Percentage of treated warts cleared with treatment, as measured with dermatoscopic examination, after 12 weeks.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. common warts on non-genital, non-facial skin
  2. otherwise healthy
  3. between 18-65 and able to give informed consent
  4. capable of tolerating treatment

Exclusion Criteria:

  1. Ill-health
  2. Poor tolerance or sensitivity to treatments in study
  3. <18 years old; >65 years old
  4. verruca plana or condyloma acuminata
  5. immunosuppression or immune dysfunction
  6. significant peripheral vascular disease
  7. significant sensitivity to cold
  8. epidermodysplasia verruciformis
  9. mosaiform warts or periungual warts

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01084824

Layout table for location information
United States, Idaho
North Idaho Dermatology
Coeur D'Alene, Idaho, United States, 83814
Sponsors and Collaborators
North Idaho Dermatology
Layout table for investigator information
Principal Investigator: Richard A Flygare, PhD TUI University; North Idaho Dermatology
Layout table for additonal information
Responsible Party: Richard Flygare, Ph.D.; Stephen Craig, M.D., North Idaho Dermatology, TUI University Identifier: NCT01084824    
Other Study ID Numbers: NID-001
First Posted: March 11, 2010    Key Record Dates
Last Update Posted: March 11, 2010
Last Verified: March 2010
Keywords provided by North Idaho Dermatology:
Verruca vulgaris
Liquid Nitrogen
combination treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Tumor Virus Infections
Skin Diseases, Infectious
Skin Diseases
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action